## Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:		NEW ASSIGNMENT	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:		ASSIGNMENT	ASSIGNMENT	
CONVEYING PARTY	DATA			
		Name	Execution Date	
Steven M. Ruben			07/28/2005	
Craig A. Rosen			08/03/2005	
RECEIVING PARTY	DATA			
Name:	Human Genome Sciences, Inc.			
Street Address:	14200 Shady Grove Road			
City:	Rockville			
State/Country:	MARYLAND			
Postal Code:	20850			
PCT Number:		US0313414		
Property Type		Numbe	r	
Application Number:		Number     US0313414     10513705		
CORRESPONDENCI Fax Number:	(301)309	9-8439 Mail when the fax attempt is unsuccessfu	1	
Phone: 240-314-1224				
Email: mark_hyman@hgsi.com				
Correspondent Name: Mark J. Hyman				
Address Line 1: 14200 Shady Grove Road   Address Line 2: Intellectual Property Dept.				
Address Line 2:Intellectual Property Dept.Address Line 4:Rockville, MARYLAND 20850				
NAME OF SUBMITTER:		Mark J. Hyman		
Total Attachments: 2 source=PF589US ass	signment#page1	tif		

## ASSIGNMENT

For good and valuable consideration, the receipt of which is hereby acknowledged, each of the undersigned, Craig A. Rosen and Steven M. Ruben, hereby sells, assigns, transfers, and sets over to Human Genome Sciences, Inc. ("Assignee") having a place of business at 14200 Shady Grove Road, Rockville, MD 20850, its successors, assigns and legal representatives, his/her entire right, title and interest, including the right to sue and collect for all past, present and future damages, for the United States of America, including all its territories and possessions, and all other countries,

- (a) in and to the invention known as <u>Antibodies That Specifically Bind to Chemokine Beta-4</u>, for which International Application No. <u>PCT/US2003/013414</u> was filed on <u>April 30, 2003</u>, designating the United States, which entered the U.S. national stage as U.S. Application No. 10/513,705 on November 8, 2004, in any and all applications thereon, in any and all Patent(s) therefor, and
- (b) in any and all applications that claim the benefit of the patent application listed above in part (a), including continuing (continuation, divisional) applications, reissues, extensions, renewals and reexaminations of the patent application or patent therefor listed above in part (a), to the full extent of the term or terms for which patents issue, and
- (c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals, and examinations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

Each of the undersigned further agrees that said Assignee may apply for and receive patent(s) for said invention(s) in its own name; and agrees to execute all papers necessary in connection with said application(s) and any continuing application(s) (continuation, divisional, or continuation-in-part), substitutes, renewals, reissues, reexaminations, extensions, and all other patent applications on all such invention(s), including all rightful oaths, declarations, powers of attorney and other papers; and agrees to execute separate assignments in connection with such application(s) as the Assignee may deem necessary and expedient; and agrees to communicate to said Assignee, its successors, assigns, and representatives all facts known to the undersigned relating to said invention(s) and the history thereof; and agrees to cooperate fully and completely with said Assignee, its successors, assigns, and representatives in securing, maintaining, and enforcing proper patent protection for said invention(s) and for vesting title to said invention(s) and all patent application(s) and all patents on said invention(s) in Assignee, its successors, assigns and representatives.

Each of the undersigned agrees to execute all papers necessary in connection with any interference that may be declared or litigation that may be instituted concerning the application(s) or patent(s) referred to above and to cooperate fully and completely with the Assignee, its successors, assigns, and representatives in obtaining evidence and going forward with such interference or litigation, including providing testimonial evidence.

Page 1 of 2

Docket No.: PF589US PATENT REEL: 016499 FRAME: 0707 Each of the undersigned hereby represents and warrants to Assignee, its successors, assigns and representatives that no assignment, grant, mortgage, license or other right or agreement affecting the rights and property herein conveyed has been or will be made to others by the undersigned and that full right to convey the same as expressed herein is possessed by the undersigned.

Each of the Practitioners at **Customer Number 22195** is hereby granted with full power to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, this Assignment is executed by the undersigned on the date(s) opposite their signature(s):

-13/03 - 10.1 m Inventor's Signature Date: Craig A. Rosen Inventor's Signature: Date Steven M. Ruben

Docket No.: PF589US PATENT REEL: 016499 FRAME: 0708

## **RECORDED: 09/07/2005**